Zhou Wei, Zhou Hui, Liu Yuan-Yuan, Li Meng-Xuan, Wu Xiao-Han, Liang Jiao, Hao Jing, Liu Sheng-Nan, Jin Chun-Jie
Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Department of Ophthalmology, Shanxi Yuncheng Tongde Hospital, Yuncheng 044000, Shanxi Province, China.
Int J Ophthalmol. 2024 Aug 18;17(8):1469-1476. doi: 10.18240/ijo.2024.08.12. eCollection 2024.
To describe the multimodal imaging features, treatment, and outcomes of patients diagnosed with adult-onset Coats disease.
This retrospective study included patients first diagnosed with Coats disease at ≥18 years of age between September 2017 and September 2021. Some patients received anti-vascular endothelial growth factor (VEGF) therapy (conbercept, 0.5 mg) as the initial treatment, which was combined with laser photocoagulation as needed. All the patients underwent best corrected visual acuity (BCVA) and intraocular pressure examinations, fundus color photography, spontaneous fluorescence tests, fundus fluorescein angiography, optical coherence tomography (OCT), OCT angiography, and other examinations. BCVA alterations and multimodal image findings in the affected eyes following treatment were compared and the prognostic factors were analyzed.
The study included 15 patients who were aged 24-72 (57.33±12.61)y at presentation. Systemic hypertension was the most common associated systemic condition, occurring in 13 (86.7%) patients. Baseline BCVA ranged from 2.0 to 5.0 (4.0±1.1), which showed improvement following treatment (4.2±1.0). Multimodal imaging revealed retinal telangiectasis in 13 patients (86.7%), patchy hemorrhage in 5 patients (33.3%), and stage 2B disease (Shield's staging criteria) in 11 patients (73.3%). OCT revealed that the baseline central macular thickness (CMT) ranged from 129 to 964 µm (473.0±230.1 µm), with 13 patients (86.7%) exhibiting a baseline CMT exceeding 250 µm. Furthermore, 8 patients (53.3%) presented with an epiretinal membrane at baseline or during follow-up. Hyper-reflective scars were observed on OCT in five patients (33.3%) with poor visual prognosis. Vision deteriorated in one patient who did not receive treatment. Final vision was stable in three patients who received laser treatment, whereas improvement was observed in one of two patients who received anti-VEGF therapy alone. In addition, 8 of 9 patients (88.9%) who received laser treatment and conbercept exhibited stable or improved BCVA.
Multimodal imaging can help diagnose adult-onset Coats disease. Anti-VEGF treatment combined with laser therapy can be an option for improving or maintaining BCVA and resolving macular edema. The final visual outcome depends on macular involvement and the disease stage.
描述成人期Coats病患者的多模态成像特征、治疗方法及预后。
这项回顾性研究纳入了2017年9月至2021年9月期间首次诊断为Coats病且年龄≥18岁的患者。部分患者接受抗血管内皮生长因子(VEGF)治疗(康柏西普,0.5mg)作为初始治疗,并根据需要联合激光光凝治疗。所有患者均接受最佳矫正视力(BCVA)、眼压检查、眼底彩色照相、自发荧光检查、眼底荧光血管造影、光学相干断层扫描(OCT)、OCT血管造影等检查。比较治疗后患眼的BCVA变化和多模态图像表现,并分析预后因素。
该研究纳入了15例患者,就诊时年龄为24 - 72(57.33±12.61)岁。全身性高血压是最常见的相关全身性疾病,13例(86.7%)患者出现。基线BCVA范围为2.0至5.0(4.0±1.1),治疗后有所改善(4.2±1.0)。多模态成像显示13例(86.7%)患者有视网膜毛细血管扩张,5例(33.3%)患者有片状出血,11例(73.3%)患者为2B期疾病(Shield分期标准)。OCT显示基线中心黄斑厚度(CMT)范围为129至964µm(473.0±230.1µm),13例(86.7%)患者基线CMT超过250µm。此外,8例(53.3%)患者在基线或随访期间出现视网膜前膜。5例(33.3%)视力预后较差的患者在OCT上观察到高反射瘢痕。1例未接受治疗的患者视力恶化。3例接受激光治疗的患者最终视力稳定,而2例单独接受抗VEGF治疗的患者中有1例视力改善。此外,9例接受激光治疗和康柏西普治疗的患者中有8例(88.9%)BCVA稳定或改善。
多模态成像有助于诊断成人期Coats病。抗VEGF治疗联合激光治疗可作为改善或维持BCVA及消除黄斑水肿的一种选择。最终视觉预后取决于黄斑受累情况和疾病分期。